<DOC>
	<DOCNO>NCT00224471</DOCNO>
	<brief_summary>Evaluate , one month third dose , lot-to-lot consistency 3 different commercial scale production lot candidate vaccine healthy HSV 1-/2- female age 10-17 year , determine ELISA . Absence significant variation parameter among tested lot hypothesize .</brief_summary>
	<brief_title>Study Compare Safety Immunogenicity Commercial Scale Consistency Lots Herpes Simplex Vaccine</brief_title>
	<detailed_description>At month 0 , 1 6 , 3 group 184 subject receive 3 dos herpes simplex vaccine lot A , B C , respectively . The study take 14 month complete , include screening , 6 visit require . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy female , include , 10 17 year age time first vaccination . Seronegative HSV1 HSV2 screen Written informed assent obtain subject write informed consent obtain parent legal guardian subject prior enrolment . If subject legal age consent country , write informed consent obtain subject . Subject must negative urine pregnancy test . Subject must nonchildbearing potential , i.e . premenarcheal , childbearing potential must abstinent must use effective method birth control 30 day prior vaccination , negative urine pregnancy test must agree continue precaution two month completion vaccination series . Subjects reach menarche study therefore childbearing potential must agree follow precaution . A subject ( whose parents/guardian ) investigator believe comply requirement protocol Exclusion criterion : Pregnant lactate female . Female plan become pregnant first eight month study Any previous history , current clinical sign symptom orolabial ( cold sore ) , genital nongenital HSV disease , swell , papule , vesicle , pustule , ulcer , crust , fissure , erythema , discharge , pain , burning , itch , tingle , dysuria . Previous vaccination herpes . History erythema multiforme . Use investigational nonregistered drug vaccine study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Planned administration/administration nonstudy vaccine within 30 day first dose study vaccine follow exception : Administration routine meningococcal , hepatitis B , inactivate influenza , diphtheria/tetanus and/or diphtheria/tetanus contain vaccine 8 day first dose study vaccine allow . History allergic disease reaction likely exacerbate component study vaccines Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . History current acute chronic autoimmune disease . History neurologic disorder seizure , exception single febrile seizure childhood . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine medical history physical examination . Acute disease time enrolment Oral temperature ≥99.5°F ( &gt; 37.5°C ) / axillary temperature ≥99.5°F ( &gt; 37.5°C ) time enrolment Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose plan use study period Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period .</criteria>
	<gender>Female</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Adolescents</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Safety</keyword>
	<keyword>Herpes Simplex vaccine</keyword>
</DOC>